1. Home
  2. FEED vs BIAF Comparison

FEED vs BIAF Comparison

Compare FEED & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FEED

ENvue Medical Inc. Common Stock

N/A

Current Price

$0.32

Market Cap

5.6M

Sector

N/A

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$0.63

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEED
BIAF
Founded
2003
2014
Country
United States
United States
Employees
14
57
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FEED
BIAF
Price
$0.32
$0.63
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
272.7K
300.1K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.23
52 Week High
$6.09
$13.50

Technical Indicators

Market Signals
Indicator
FEED
BIAF
Relative Strength Index (RSI) 22.80 30.63
Support Level N/A $0.61
Resistance Level $0.97 $0.87
Average True Range (ATR) 0.03 0.05
MACD 0.01 0.02
Stochastic Oscillator 1.09 39.85

Price Performance

Historical Comparison
FEED
BIAF

About FEED ENvue Medical Inc. Common Stock

ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: